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Jennerlan prophylaxis in man by means of intradermal inoculation 
of cultured vaccine virus was described (1) in 1935.  Since then this 
type of prophylaxis against smallpox has been used by us,  by many 
private physicians, and by physicians in  a  number of clinics.  For 
the last 3 years the virus employed has been from generations 30 to 
170  of the  "second revived" strain of cultured vaccine virus,  dried 
]From the frozen state in the presence of gum acacia and sealed in vacuo 
(1, 2).  This strain (3) was originally derived from calf lymph vaccine 
virus supplied by the New York City Board of Health in 1931 and has 
been propagated since then by serial transfers in a medium consisting 
of Tyrode's solution and minced chick embryo tissue.  Intradermal 
inoculation of the virus in rabbits reveals that it maintains a uniform 
potency during  continued  cultivation.  Moreover,  the  lesions  pro- 
duced in rabbits are less severe than are those caused by other strains 
of vaccine virus. 
When  inoculated  intradermally  in  susceptible  persons,  cultured 
vaccine virus produces a high percentage of positive reactions.  The 
percentages reported by those to whom the virus has been dispensed 
have ranged from 80 to 100; it is probable that an average of over 90 
per cent has been obtained in a minimum of 6000 to 7000 intradermal 
vaccinations.  In our experience with more than 200 primary vaccina- 
tions the incidence of "takes" has been 100 per cent.  Typical positive 
reactions appear as  small  red papules  on  the 4th  to  9th  day after 
inoculation.  Erythema and induration increase until the lesions are 
2 to 4 cm. in diameter at their height 4 to 6 days later.  Erythema 
disappears rapidly although induration may persist 4 or 6 weeks.  If 
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the inoculation is  made properly, no vesicle forms to  leave a  scar. 
Those who have observed or experienced reactions produced in this 
way have been pleased by the lack of accompanying constitutional 
symptoms and the absence of open sores. 
Knowledge of the amount and duration of immunity to  smallpox 
induced by the intradermal injection of cultured vaccine virus is of 
cardinal  importance.  However,  no  opportunity  of  observing  the 
incidence of  smallpox  in  a  group of individuals vaccinated in  this 
manner has arisen.  Nevertheless, from experience it is known that 
the efficacy of any type of vaccination against smallpox can be tested 
by revaccination with a  potent calf lymph vaccine virus.  In spite 
of this fact, reports of the effect of primary vaccination with cultured 
vaccine virus on subsequent revaccination with calf lymph virus have 
been few.  In 1935 (I) we described the results obtained in the revac- 
cination  of  7  persons  who  had  been  successfully vaccinated with 
cultured virus 1S days to 7 months previously.  Of these, 6 were im- 
mune to New York City calf lymph virus, while 1, after an interval 
of 7 months, responded with an  accelerated take.  In  1937 (4)  we 
conducted revaccinations on a small group of children who had been 
vaccinated with cultured vaccine virus 1 month to 2~ years previously. 
In 6 of 14 such children the response to calf lymph virus was that of 
an accelerated take, i.e.,  vesicles  formed and the reactions were not 
at their maximum until the 5th or 6th day. 
During the last year and a  half we  have studied a large group of 
children  in  order to  obtain  more complete  information concerning 
the amount and duration of immunity produced by cultured vaccine 
virus against the New York City calf lymph strain of  virus.  The 
results of the study will be reported at this time.  In addition, in- 
formation regarding the immunity produced by cultured virus against 
other strains of calf lymph vaccine virus, as well as a  consideration 
of the  effect that  differences in  the manner of performing primary 
inoculations with cultured virus have on subsequent immunity, will 
be presented. 
Methods 
At the Rockefeller Hospital there is little opportunity of performing primary 
vaccinations, in consequence of which it has not been possible in this clinic for us 
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at the Children's Prophylactic Clinic of the New York Hospital, cultured vaccine 
virus supplied by us has been administered intradermally for several years.  The 
facilities  and records of this clinic were made available to us through the courtesy 
of Dr. Samuel Levine and Dr. Parker Dooley. 
Children were selected in whom a  positive primary vaccination with cultured 
virus had been observed and recorded and in whom no further prophylaxis against 
smallpox had  been  carried  out.  Each child  was revaccinated  with  New York 
City Board of Health calf lymph vaccine virus applied to a linear scratch ~  inch 
in length.  In addition various groups received on the opposite limb commercial 
calf lymph virus A or B applied to a linear scratch.  All virus used was received 
fresh each week from the place of preparation and was stored at 0°C. before use. 
A  single observation on the 5th day after revaccination has, as a  rule,  been all 
that  could be made;  the few that  could not be seen  on the 5th day were seen 
between the 4th to 7th days. 
The time at which a reaction to vaccine virus is at its maximum and not the 
size of the lesion is considered to be the correct index of susceptibility (5).  Reac- 
tions  are  usually  classified  as  no reaction,  immune  reaction,  accelerated  take, 
primaDr take.  Due to the impossibility of making frequent observations on the 
revaccinated children only two types of reaction are recorded, namely, immune 
reactions and accelerated takes.  Immune reactions are those which showed on the 
5th day only a small papule or some evidence that a mild response to inoculation 
had been present.  The children who showed at this  time no evidence that  the 
virus had been effectively introduced into the skin were excluded from considera- 
tion.  Thus, a few rapid immune reactions may have been missed, but the number 
was not great enough to affect significantly the results of the study.  Accelerated 
reactions comprise those which on the.Sth  day showed the presence of a  vesicle 
surrounded by a  zone of erythema.  The use of vesicle formation as one of the 
criteria~or classification has insured the inclusion in the group of accelerated takes of 
even the mildest of this kind of reaction, v/z., one which heals without the forma- 
tion of an enduring scar.  It is possible that some of the reactions may have been 
in an early stage when the results were recorded and that the time at which the 
maximum sizes were reached approached closely the time at which primary takes 
would have been at  their height.  However, from observation of some children 
later than the 5th day after inoculation and from the size of resultant scars which 
we have seen,  we believe  that  most of the accelerated  reactions were correctly 
classified. 
Results of  Revaccinatlon witk  New  York  City  Calf  Lymph  Vaccine 
Virus of Children Who Had Received One Successful Intradermal 
Inoculation of Cultured Vaccine Virus 
331  children  who  had  received  one  inoculation  of  cultured  virus 
resulting in a primary take 1 month to 3 years and 9 months previously 
were  revaccinated  with  New  York  City  calf lymph  virus  (Table  I). 860  IMMUNITY  TO  VACCINIA 
Of these, 82 or 25 per cent responded with immune reactions, while 
249 or 75 per cent showed accelerated takes.  Most of the accelerated 
reactions were mild in character, presenting a small vesicle surrounded 
by a zone of erythema 0.5 to 1 cm. in width.  Frequently on the 5th 
day the contents of the vesicles were drying or inquiry revealed that 
the lesions had been larger or as large on the preceding day.  Children 
responding in this manner did not present the usual symptoms and 
signs that as a rule accompany primary vaccination with calf lymph. 
There were others, however, in whom the lesions presented no signs 
TABLE  I 
Results of Revaccination wi~h New York  City  Vaccine Virus of Children Who Had 
Received One Successful Intradermal Inoculation of Cultured Virus 
Number of 
children 
revacclnated 
39 
76 
185 
31 
"Ilme betweenprimary 
and secondary 
va~x.iua~ons 
1-6  mos. 
6 mos.-1 yr. 
1-2 yrs. 
2+ yrs. 
Immune reactions 
Number  Percent 
13  33 
25  33 
37  20 
7  23 
82  25 
Accelerated takes 
Total 
331 
Distribution of age at time of primary vaccination similar for all groups. 
Number  Per cent 
26  67 
51  67 
148  80 
24  77 
249  75 
of regression on the 5th day and who experienced  later fever and lymph 
gland enlargement accompanying the presence of a central pustule in 
a  zone of erythema and induration of considerable extent.  Never- 
theless, healing of these lesions was rapid and the scars which resulted 
were small  and superficial. 
Analysis of the data obtained in this group of 331 children revealed 
that  the proportion of immune individuals was fairly constant and 
bore no relation to the interval which had elapsed between the primary 
vaccination with cultured virus  and revaccination with  calf lymph 
(Table  I).  It  is  true  that  the percentage of  accelerated reactions 
was slightly higher in the children revaccinated after 1 year and that 
the more severe reactions were observed in this group, but the figures 
obtained give little indication that susceptibility to calf lymph virus 
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It  is  known  that  infants  shortly  after  birth  (6)  are  somewhat 
resistant to infection with vaccine virus.  Furthermore, it has been 
demonstrated  (6)  that  such  infants  after  a  successful  vaccination 
rapidly  lose  their  immunity, many being  fully  susceptible  a  year 
later.  The results obtained in our group of 331 children, the majority 
of whom were first vaccinated between the ages of 6 months and I year, 
indicate that the differences in the age at which the primary vaccina- 
tions were performed had no influence on the proportion of children 
TABLE  II 
Results of Dermal Revaccination Made with New York City Vaccine Virus tO 
Ascertain the Duration of Immunity Produced by One Successful Intradermal 
Inoculation of Cultured Virus in Relation to the Age of Children at Time of 
Primary Vaccination 
Number of 
children 
revacclnated 
69 
98 
55 
35 
53 
21 
Total 
331 
Age when  first vaccinated 
6-9 mos. 
9 mos.-1 yr. 
1-2 yrs. 
2-3 yrs. 
3-5 yrs. 
5+ yrs. 
Tmmazne  reactions 
Number  Per cent 
15  22 
29  30 
14  25 
7  2O 
11  21 
6  29 
82  25 
Accelerated takes 
Number  Per cent 
54  78 
69  70 
41  75 
28  80 
42  79 
15  71 
249  75 
Distribution of interval of time between primary and secondary  vaccinations 
similar for all groups. 
who  retained complete immunity during the period of observation 
(Table II). 
Results of Revaccination  with Commercial Strains of Vaccine  Virus of 
Children Who Had Received One Successful Intradermal 
Inoculation of Cultured  Vaccine Virus 
Reports in  the literature concerning the duration of immunity in 
children to vaccine virus are conflicting.  Moreover,  in attempting 
to evaluate the results of different workers, one is confused by a  lack 
of uniformity in classification  or description of the type of reaction 
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of the viruses used for the primary vaccinations and revaccinations 
was either not known or not stated.  A mildly acting virus does not 
always fully protect for a great length of time against a virulent strain, 
and  results obtained by revaccination with a  mild strain  may not 
parallel  those  secured by  revaccination with  a  potent  virus.  The 
New York City vaccine virus is  a  strain of high uniform potency. 
Consequently, it seemed of interest to compare the results obtained by 
TABLE  III 
Results  of Derma~ Revaccination with  Commercial Strain~  of  Vaccine Virus  of 
Children Who Had  Received One Successful  Intradermal  Inoculation  o/ 
Cultured Virus 
Number of 
children 
revaccinated 
78 
82 
Rcvaccinated  with 
New York City virus 
Per cent  Per cent 
hnmune  accelerated 
reactions  takes 
22  78 
35  65 
Revacdnated  with 
commercial virus A 
Per cent  Per cent 
immune  accelerated 
reactions  takes 
72  28 
Revaccinated with 
commercial virus B 
Per cent  .  Per cent 
immune  accelerated 
reactions  takes 
L 
55  [  45 
Distribution of age at time of prmmry  vaccination  and interval of time between 
primary and secondary  vaccinations  similar in both groups. 
means of its use in the revaccination of children with those secured by 
revaccination with other strains of calf lymph vaccine virus. 
Two commercial preparations of calf lymph virus, A and B, were 
chosen because they are products widely used in the United States. 
78 of the 331  children who were revaccinated with New York City 
calf lymph received at the same time an inoculation with commercial 
lymph A; a second group of 82 children received in addition to New 
York City virus an inoculation of commercial calf lymph B.  Of the 
78  children, 17  or 22 per cent responded with immune reactions to 
New York City virus, while 56 or 72 per cent responded with immune 
reactions to calf lymph A; of the 82 children, 29 or 35 per cent were 
immune to New York City virus, while 45 or 55 per cent responded 
in that manner to calf lymph B.  These figures, recorded in Table III, 
show discrepancies that may result from the use of different strains 
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Effect of Differences in Primary Inoculation of Cultured Vaccine Virus 
on Subsequent Revacclnation with New York City Board of 
Health Calf Lymph 
At this point it seemed of value to learn whether the administration 
of large doses of the mildly acting cultured virus or the production of 
2 intradermal lesions at the same time would influence the resultant 
immunity.  Accordingly, a  group of children at the New York Hos- 
pital Clinic were given 2 intradermal inoculations, one in each arm or 
thigh,  of cultured vaccine virus.  There were no untoward results. 
The simultaneous evolution of 2 intradermal vaccinal lesions produced 
by  cultured vaccine virus apparently caused the  children no more 
inconvenience than  that  evoked by  a  single  reaction.  From  this 
group of children, 66, whose records showed that they had had 2 suc- 
cessful  simultaneous  primary  vaccinations,  were  revaccinated der- 
really with New York City calf lymph 2 to 6 months later.  Of the 65 
children,  18 or 27 per cent responded with immune reactions, while 
48 or  73  per cent showed accelerated takes.  Comparison of these 
figures (Table IV) with those obtained in the group of 331  (Table I) 
who received only a  single injection of cultured virus for primary 
vaccination shows that the introduction of a  double amount of this 
virus and the production of 2 primary lesions instead of one did not 
alter the percentage of children who retained for 6 months complete 
immunity to the New York City calf lymph. 
~As stated previously, the virus which has been used during the last 
3 years was obtained from the 50th to the 170th culture generations 
of the "second revived" strain.  This virus was selected for human 
inoculation  because  it  produced mild  reactions  and  maintained  a 
constant potency for man and rabbit.  However, from previous ex- 
perience (2) with the original strain we had noted that the infectivity 
of the virus diminished on repeated passage in  culture and that  a 
change in the character of the lesions produced by it in rabbits also 
occurred  during  serial  transfer  of  the  virus  in  the  medium used. 
It occurred to us that a gradual change might have taken place in the 
"second revived" strain, less marked than that noted in the original 
one  but  still  great  enough  to  influence  the  amount  of  protection 
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smallpox.  Therefore,  it  seemed  important  to  determine  whether 
continued cultivation of the "second revived" strain had resulted in a 
loss of some of its antigenicity essential for the development of a lasting 
immunity.  In order to make this determination,  cultured virus from 
the 20th to the 30th ~enerations of the  "second revived" strain  was 
prepared for human  inoculation and tested in rabbits and in man. 
Intradermal  inoculation  of the  virus  in  rabbits  revealed that  the 
infectivity or titer was essentially the same as that  of generation  50 
to  170,  but the lesions produced by the early generations were more 
edematous  and  more  hemorrhagic  and  necrotic  than  were  those 
TABLE  IV 
Results  Obtained by Dermal  Revaccination  witk New  York  City  Vaccine  Virus of 
Children Who Had Been  Primarily  Vaccinated  Intradermally  in Several 
Different Ways with Cultured Virus 
Type  of  primary inoculstion 
Single inoculation with virus from 50-170th culture 
generation 
Double  inocul~tinn with virus  from 50-170th culture 
generation 
Single inoculation with virus from 20-30th culture 
generation 
I 
Numbex 
children 
[~revac- 
66 
54 
Nunl~er 
of 
immune 
reac- 
tions 
18 
33 
Percent 
immune 
tlons 
27 
61 
~mber 
of 
,ccel- 
rated 
akes 
~49 
48 
21 
Per cent 
of 
~ccel- 
er~ted 
takes 
75 
73 
39 
produced by later generations of the active agent.  Each of 7 volun- 
teers was inoculated intradermally  with 0.1  cc. of a  1:10 dilution  of 
the virus.  The lesions produced by this material were larger and more 
severe than those caused by virus from later generations; however, the 
reactions were not severe enough to cause anxiety regarding  the use 
of the material.  Consequently, a  study of immunity produced by it 
was  carried  out  in  a  group  of  children  at  the  New York  Hospital 
Prophylactic Clinic.  54 children were inoculated intradermally  with 
cultured virus from generations 20 to 30; 2 to 6 months later they were 
reinoculated dermally with the New York City calf lymph virus.  Of 
the 54 children,  21  or 39 per cent responded with accelerated takes, 
while 33 or 61 per cent showed immune  reactions  (Table IV).  The 
accelerated  takes  were mild  and  healed  quickly leaving  only  small 
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obtained in  children primarily vaccinated with  virus  from  culture 
generations 50 to 170. 
DISCUSSION 
Vaccination against  smallpox by means of dermal application of 
potent  calf lymph vaccine virus  is  efficacious.  Nevertheless,  con- 
siderable inconvenience and, at times, danger are associated with this 
type of vaccination which always leaves an ugly scar.  In view of these 
facts, many people in the United States have never been vaccinated. 
To overcome opposition  to  vaccination certain health officials min- 
imize the inconvenience and speak of the scar as a "badge of health." 
Thus, they leave the impression that a person with a scar is protected 
against  smallpox  and  is  not  in  need  of  revaccinations  at  regular 
intervals.  As a  matter of fact,  all that a  scar indicates is that an 
individual has been vaccinated; it does not show that the person is 
immune to smallpox.  That can be determined only by the results of 
revaccination with a potent calf lymph virus.  Moreover, the longer 
a person has gone since a primary vaccination, the more likely is he to 
have lost  protection and  the  greater is  his  need of revaccination. 
Some individuals lose  immunity more rapidly than  do  others;  this 
appears to be particularly true of young children and infants.  There- 
fore, revaccinations should be made at regular intervals; in the pres- 
ence of smallpox epidemics revaccinations should be made regardless 
of when primary vaccinations or revaccinations were performed. 
With  the idea  that  vaccination against smallpox can be  made a 
safer procedure,  that  mutilation is  not  an  essential feature of  the 
procedure, and that a scar gives the individual as well as the health 
officer a false sense of security, we undertook a number of years ago 
to prepare a vaccine virus that could be used in a manner less objec- 
tionable than that now employed with calf lymph virus.  From the 
results obtained by us in the use of cultured vaccine virus for Jennerian 
prophylaxis in man we have* become convinced that the ideas which 
prompted the work are entirely sound. 
Continued cultivation of vaccine virus in the medium used by us 
has  brought about  a  qualitative change in  the  active agent which 
makes it possible  to introduce considerable mounts of the material 
intradermally without danger and inconvenience to patients.  It has 
been found, however, that the amount of immunity produced by the 866  IMMUNITY TO  VACCINIA 
cultured virus,  as  tested by  means of  a  highly potent calf  lymph 
vaccine virus, would probably not be considered sufficient for complete 
protection against smallpox.  On the other hand, when commercial 
vaccines widely used in the United States are employed for testing 
the immunity induced by  the  cultured virus,  the  results might be 
considered satisfactory.  At present we are suggesting that primary 
vaccinations be made intradermally with our cultured virus and that 
revaccinations be made dermally six months to a year later by means 
of a potent calf lymph virus.  In this way vaccinated individuals will 
not become sick and will not be subjected to the dangers associated 
with primary vaccinations with calf lymph virus, but will obtain a 
solid and lasting immunity to  smallpox.  It is possible  and highly 
probable that a cultured virus can be developed which will be suitable 
for intradermal use and will not require prompt dermal revaccinations 
with a  potent calf lymph virus to produce an  enduring immunity. 
These are matters for future investigation. 
CONCLUSIONS 
Continued cultivation of vaccine virus in a  medium consisting of 
minced chick embryo tissue and Tyrode's solution has resulted in a 
virus  qualitatively  changed  to  such  an  extent  that  considerable 
amounts of it can be injected intradermally into human beings without 
danger or inconvenience. 
Individuals who  are  vaccinated intradermally  with  the  cultured 
virus should be revaccinated dermally six months to a year later with 
a potent calf lymph virus in order to obtain a satisfactory immunity 
to smallpox without being subjected to the dangers and inconvenience 
associated with primary vaccinations with calf lymph virus. 
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